PharmaSGP Holding SE Issues Statement on Delisting Offer by FUTRUE GmbH

PharmaSGP Holding SE published a joint reasoned statement by its Management and Supervisory Boards on the delisting tender offer by FUTRUE GmbH. The Boards consider the offer of €28.00 per share adequate from a financial standpoint. However, they expressed a neutral position, refraining from recommending whether shareholders should accept the offer.

The acceptance period started on July 14, 2025, and will end on August 11, 2025. Shareholders are advised to review the complete reasoned statement available on PharmaSGP’s website under "The Share / Delisting" section. Detailed offer information can be found on the Bidder's website.

This release emphasizes that only the Boards' reasoned statement is authoritative, and advises shareholders to consider it in full before making their decisions.